Latest Breaking News On - Investigational therapeutics - Page 3 : comparemela.com

Tinengotinib Elicits Clinical Benefit in Pretreated Cholangiocarcinoma and Other Advanced Solid Tumors

Sanjay Goel, MD, MS, expands on the findings from the phase 1b/2 trial, noting the potential benefit this approach may have for patients with cholangiocarcinoma, and detailed next steps for investigating tinengotinib.

Sanjay goelRutgers cancer institute of new jerseyDivision of medical oncologyInvestigational therapeuticsMedical oncologySolid tumorRutgers robert wood johnson medical schoolRutgers cancer instituteNew jerseyNew brunswickRwjbarnabas health and rutgers cancer institute of new jerseyProstate cancerGastrointestinal cancerBreast cancer

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.

Salt lake cityUnited statesUniversity of utahNeeraj agarwalAshling wahnerHuntsman cancer instituteGenitourinary oncology programCancer researchPresidential endowed chairInvestigational therapeuticsSalt lakeApple podcastsGoogle podcastsAmazon musicFda approval of talazoparib plus enzalutamidePatients with metastatic castration resistant prostate cancer harboring homologous recombination repair gene mutations

Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer

Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.

Neeraj agarwalHuntsman cancer instituteGenitourinary oncology programCancer researchEuropean unionUniversity of utahPresidential endowed chairInvestigational therapeuticsParp inhibitors in metastatic castration resistant prostate cancerMetastatic castration sensitive prostate cancer

Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC

Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Neeraj agarwalUniversity of utahHuntsman cancer instituteCancer researchGenitourinary oncology programPresidential endowed chairInvestigational therapeutics

Dr Goel on the Preliminary Efficacy of Tinengotinib Monotherapy in Advanced Solid Tumors

Sanjay Goel, MD, MS, discusses the preliminary efficacy of tinengotinib monotherapy in advanced solid tumors according to data from a phase 1b/2 trial (NCT04742959).

Sanjay goelDivision of medical oncologyRutgers robert wood johnson medical schoolInvestigational therapeuticsMedical oncologySolid tumor